Azurity Pharmaceuticals Acquires Sebela's Bowel Prep Franchise as Sebela Advances GERD Drug Tegoprazan to FDA Submission
核心洞察
Azurity Pharmaceuticals (搜索) successfully acquired Sebela Pharmaceuticals (搜索)' Bowel Prep Franchise, including two leading bowel preparation therapies for colonoscopies, expanding its gastrointestinal portfolio.
The strategic transaction brings more than 50 commercial and support team members from Sebela to Azurity, strengthening the company's presence in gastroenterology.
Sebela Pharmaceuticals (搜索) will focus on developing tegoprazan, a novel potassium competitive acid blocker (搜索) (PCAB) for GERD treatment, with FDA submission planned this quarter.
Azurity Pharmaceuticals (搜索) announced the successful acquisition of Sebela Pharmaceuticals (搜索)' Bowel Prep Franchise on November 17, 2025, marking a strategic expansion of its gastrointestinal portfolio. The transaction includes two leading bowel preparation therapies for colonoscopies and brings more than 50 commercial and support team members from Sebela to Azurity.
Strategic Expansion in Gastroenterology
Ronald Scarboro, CEO of Azurity Pharmaceuticals (搜索), emphasized the acquisition's alignment with the company's growth strategy. "We are pleased to welcome Sebela Pharmaceuticals (搜索)' GI team and product portfolio to Azurity. This strategic acquisition aligns with our long-term growth priorities by strengthening our presence in Gastroenterology and further diversifying our portfolio of medicines," Scarboro stated.
The acquisition enhances Azurity's commitment to serving overlooked patients by advancing access to medicines. By integrating Sebela's bowel prep franchise, Azurity will expand its product offerings and capabilities to healthcare providers and patients in the United States.
Sebela's Focus on Novel GERD Treatment
Following the divestiture, Sebela Pharmaceuticals (搜索) will concentrate on developing innovative treatments for gastroesophageal reflux disease (搜索) (GERD). Alan Cooke, President and CEO of Sebela Pharmaceuticals, expressed confidence in the transaction while highlighting the company's pipeline priorities. "Azurity Pharmaceuticals (搜索) will be a strong and strategic home for our bowel prep franchise and the talented commercial team supporting it," Cooke said.
Sebela's primary focus centers on tegoprazan, a novel potassium competitive acid blocker (搜索) (PCAB) that has completed its Phase 3 program in gastroesophageal reflux disease (搜索). The drug specifically targets erosive esophagitis (搜索) (EE) and non-erosive reflux disease (搜索) (NERD). Cooke noted the company's excitement about tegoprazan's potential as they prepare to submit a new drug application to the FDA this quarter.
Company Profiles and Market Position
Sebela Pharmaceuticals (搜索) operates as a gastroenterology-focused company in the US, also developing innovative products in women's health. Through its subsidiary Braintree Laboratories (搜索), Inc., the company has been innovating, developing, manufacturing and commercializing gastroenterology products for over 40 years.
Azurity Pharmaceuticals (搜索) maintains a global footprint spanning over 50 countries, with a diversified portfolio of more than 50 marketed brands across 10 dosage forms and 10 key therapeutic areas. The privately held company leverages its Next-Gen Commercial Model, utilizing data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement.
Transaction Details
The strategic transaction involved comprehensive advisory support from leading financial and legal firms. Barclays served as financial advisor and Eversheds Sutherland provided legal counsel to Azurity, while Jefferies acted as financial advisor and Mayer Brown served as legal advisor to Sebela for the transaction.
Both companies committed to ensuring a smooth transition for employees, customers, and partners as the integration proceeds.